Salvia BioElectronics

15/10/2026

PRESS RELEASE 📢 | 𝗔 𝗻𝗲𝘄 𝗰𝗵𝗮𝗽𝘁𝗲𝗿 𝗶𝗻 𝗼𝘂𝗿 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗽𝗿𝗼𝗴𝗿𝗮𝗺 𝘀𝘁𝗮𝗿𝘁𝘀 𝘁𝗼𝗱𝗮𝘆!

Today, we announce that the first patient in the U.S. has been implanted with the investigational MySalvia System in RECLAIM-II, our pivotal study in adults with resistant migraine.

For people living with resistant migraine, trying multiple preventive treatments does not always mean finding sufficient relief. The burden can remain profound.

RECLAIM-II will evaluate the safety and effectiveness of our purpose-built neuromodulation system in approximately 150 patients across more than 20 sites in the United States.

This first implantation in the U.S. represents years of work across our clinical program, and an important next step in building the rigorous evidence needed to understand the potential role of neuromodulation in migraine care.

We’re deeply grateful to the patients, investigators, clinical teams and everyone at Salvia who is making this study possible. Together, we’re moving closer to our mission of empowering people with migraine to reclaim their lives.

🔗 Read the full announcement: https://www.salviabioelectronics.com/news/salvia-bioelectronics-initiates-pivotal-study-with-first-patient-in-the-u-s-receiving-ultra-thin-neuromodulation-implant-for-resistant-migraine



𝘊𝘈𝘜𝘛𝘐𝘖𝘕 – 𝘐𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘥𝘦𝘷𝘪𝘤𝘦. 𝘓𝘪𝘮𝘪𝘵𝘦𝘥 𝘣𝘺 𝘍𝘦𝘥𝘦𝘳𝘢𝘭 (𝘰𝘳 𝘜𝘯𝘪𝘵𝘦𝘥 𝘚𝘵𝘢𝘵𝘦𝘴) 𝘭𝘢𝘸 𝘵𝘰 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘶𝘴𝘦.

Press release - Salvia BioElectronics, a clinical-stage medical device company pioneering a novel neuromodulation therapy for people with resistant migraine, today announced that the first patient has been implanted with the MySalvia System in RECLAIM-II, the company’s pivotal trial evaluating the...

12/10/2026

𝗗𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝘁 𝘁𝗲𝗮𝗺𝘀. 𝗢𝗻𝗲 𝘀𝗵𝗮𝗿𝗲𝗱 𝗴𝗼𝗮𝗹.

Yesterday, 16 Salvia colleagues took part in the ASML Marathon Eindhoven Business Run as 4 relay teams. 💪
This colleague-led initiative, supported by Salvia, brought together people from across the company. Colleagues from different functions joined forces, each contributing their part and trusting others to carry the baton forward.

That teamwork was visible throughout the day. When injuries and illness prevented some runners from participating, colleagues stepped in without hesitation. A special thank you to Eimear and Abdel for helping ensure every team could make it to the start line.

Team "The Green Machine" recorded the fastest Salvia time at 3h54m, with the other teams close behind.

Along the course, fellow colleagues, family members, and friends cheered the runners on, making it a true team effort from start to finish.

What we'll remember most isn't the finishing times, but people coming together, supporting each other, and giving their best for a shared goal.

Congratulations to all participants and supporters. 👏 💚

01/10/2026

𝗪𝗵𝗲𝗿𝗲 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲, 𝘀𝗰𝗶𝗲𝗻𝗰𝗲, 𝗮𝗻𝗱 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗰𝗼𝗺𝗲 𝘁𝗼𝗴𝗲𝘁𝗵𝗲𝗿 𝘁𝗼 𝗮𝗱𝘃𝗮𝗻𝗰𝗲 𝗻𝗲𝘂𝗿𝗼𝗺𝗼𝗱𝘂𝗹𝗮𝘁𝗶𝗼𝗻

This week, our Medical Science Liaison, Pete Morris, joined fellow experts at the MedTech Inspiration Event on Neuromodulation, organized by Brightlands Maastricht Health Campus at MECC Maastricht.

Together with speakers from Medtronic, ONWARD Medical, Maastricht UMC+, Maastricht University, DEMCON, and CorTec, discussions focused on the future of neuromodulation in healthcare and the importance of collaboration across healthcare, science, and industry.

At Salvia, we are developing a purpose-built neuromodulation system for people with migraine. Keeping the patient perspective at the center of innovation is fundamental to how we approach the opportunities and challenges ahead for the field.

Thank you to Brightlands Maastricht Health Campus for bringing together such a diverse group of experts and innovators and creating a valuable platform for knowledge sharing and discussion.

📸 Photos by Marcel van Hoorn



𝘔𝘺𝘚𝘢𝘭𝘷𝘪𝘢 𝘛𝘩𝘦𝘳𝘢𝘱𝘺 𝘪𝘴 𝘢𝘯 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘥𝘦𝘷𝘪𝘤𝘦, 𝘭𝘪𝘮𝘪𝘵𝘦𝘥 𝘵𝘰 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘶𝘴𝘦 𝘪𝘯 𝘢𝘤𝘤𝘰𝘳𝘥𝘢𝘯𝘤𝘦 𝘸𝘪𝘵𝘩 𝘢𝘱𝘱𝘭𝘪𝘤𝘢𝘣𝘭𝘦 𝘳𝘦𝘨𝘶𝘭𝘢𝘵𝘪𝘰𝘯𝘴 𝘪𝘯 𝘵𝘩𝘦 𝘜𝘯𝘪𝘵𝘦𝘥 𝘚𝘵𝘢𝘵𝘦𝘴 𝘢𝘯𝘥 𝘌𝘶𝘳𝘰𝘱𝘦

26/09/2026

𝗠𝗶𝗴𝗿𝗮𝗶𝗻𝗲 𝗶𝘀 𝗮 𝘀𝗲𝗿𝗶𝗼𝘂𝘀 𝗮𝗻𝗱 𝗰𝗼𝗺𝗽𝗹𝗲𝘅 𝗻𝗲𝘂𝗿𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝘁𝗵𝗮𝘁 𝗰𝗮𝗻 𝗵𝗮𝘃𝗲 𝗮 𝗽𝗿𝗼𝗳𝗼𝘂𝗻𝗱 𝗶𝗺𝗽𝗮𝗰𝘁 𝗼𝗻 𝗱𝗮𝗶𝗹𝘆 𝗹𝗶𝗳𝗲.

Today, Salvia BioElectronics is featured in a health publication distributed with the Belgian national newspaper De Morgen. The article explores the potential of neuromodulation in migraine care and highlights the ongoing RECLAIM study in Belgium and the Netherlands.

As we continue to investigate MySalvia Therapy, we remain committed to advancing research that could help define the future role of neuromodulation in migraine treatment.

Learn more about the RECLAIM study: https://www.salviabioelectronics.com/clinical-studies



𝘔𝘺𝘚𝘢𝘭𝘷𝘪𝘢 𝘛𝘩𝘦𝘳𝘢𝘱𝘺 𝘪𝘴 𝘢𝘯 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘥𝘦𝘷𝘪𝘤𝘦, 𝘭𝘪𝘮𝘪𝘵𝘦𝘥 𝘵𝘰 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘶𝘴𝘦 𝘪𝘯 𝘢𝘤𝘤𝘰𝘳𝘥𝘢𝘯𝘤𝘦 𝘸𝘪𝘵𝘩 𝘢𝘱𝘱𝘭𝘪𝘤𝘢𝘣𝘭𝘦 𝘳𝘦𝘨𝘶𝘭𝘢𝘵𝘪𝘰𝘯𝘴 𝘪𝘯 𝘵𝘩𝘦 𝘜𝘯𝘪𝘵𝘦𝘥 𝘚𝘵𝘢𝘵𝘦𝘴 𝘢𝘯𝘥 𝘌𝘶𝘳𝘰𝘱𝘦.

24/09/2026

𝗔𝘄𝗮𝗿𝗲𝗻𝗲𝘀𝘀 𝘀𝘁𝗮𝗿𝘁𝘀 𝘄𝗶𝘁𝗵 𝗮 𝘀𝗶𝗺𝗽𝗹𝗲 𝗮𝗰𝘁: 𝗯𝗲𝗹𝗶𝗲𝘃𝗶𝗻𝗴 𝘀𝗼𝗺𝗲𝗼𝗻𝗲.
People living with migraine often hear:
"It's just a headache."
"Everyone gets headaches."
"It can't be that bad."
Yet for many people, migraine affects much more than a single day of pain. It can influence work, family life, friendships, and overall wellbeing.

During Migraine Awareness Week, organizations such as The Migraine Trust are sharing research, experiences, and stories that highlight an important reality: many people living with migraine still feel misunderstood or not believed.

Awareness starts with understanding. Understanding starts with listening.

By taking the time to hear and share these experiences, we can help build greater understanding of what it's really like to live with migraine and contribute to reducing the stigma that still surrounds this condition.

Together, we can help create a world where people living with migraine feel heard, understood, and supported.

22/09/2026

𝗟𝗮𝘀𝘁 𝘆𝗲𝗮𝗿, 𝘄𝗲 𝘁𝗼𝗼𝗸 𝘁𝗵𝗲 𝘀𝘁𝗮𝗴𝗲.
𝗧𝗵𝗶𝘀 𝘆𝗲𝗮𝗿, 𝘄𝗲 𝗵𝗲𝗹𝗽 𝘀𝗵𝗮𝗽𝗲 𝘁𝗵𝗲 𝘀𝘁𝗮𝗴𝗲.

The LEVEL UP Conference 2026 brings together founders, investors, innovators, and industry leaders from across Europe in Eindhoven, the Netherlands.

Next week, on September 28, our co-founder and CEO, Hubert Martens, will join the LEVEL UP Awards jury, helping recognize the next generation of entrepreneurs. It's a special role, one year after Salvia received the LEVEL UP Jury Award for Most Innovative Startup.

Our Chief Innovation Officer, Daniel Schobben, will also be part of the program's MedTech track, joining Andy Lürling of LUMO Labs for a conversation on investing in MedTech and turning promising innovations into real-world impact.

If you're attending LEVEL UP, come and say hello.

Whether you'd like to talk entrepreneurship, MedTech innovation, or migraine, Hubert Martens, Daniel Schobben, Ingelou Stol, and Christine Swinkels will be there from lunchtime onward. We'd love to connect.

See you in Eindhoven!

04/09/2026

𝗔 𝗰𝗼𝗹𝗼𝗿𝗳𝘂𝗹, 𝗽𝘂𝗿𝗽𝗼𝘀𝗲𝗳𝘂𝗹, 𝗮𝗻𝗱 𝗲𝘅𝗽𝗲𝗿𝗶𝗲𝗻𝗰𝗲𝗱 𝘁𝗲𝗮𝗺, 𝗮𝗹𝗹 𝗽𝘂𝗿𝘀𝘂𝗶𝗻𝗴 𝘁𝗵𝗲 𝘀𝗮𝗺𝗲 𝗺𝗶𝘀𝘀𝗶𝗼𝗻.

Our team is now spread across continents, and the mission only grows stronger: empowering people with migraine to reclaim their lives.

Yesterday, we brought together as many colleagues as we could for our annual group photo, which gets a little harder each year as more of us are an ocean away, as our clinical program advances across both Europe and the United States.

This photo matters to us. Every year, we gather by the water at High Tech Campus Eindhoven, where our journey began. Behind us, the building where we're based.

𝘔𝘺𝘚𝘢𝘭𝘷𝘪𝘢 𝘛𝘩𝘦𝘳𝘢𝘱𝘺 𝘪𝘴 𝘢𝘯 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘥𝘦𝘷𝘪𝘤𝘦, 𝘭𝘪𝘮𝘪𝘵𝘦𝘥 𝘵𝘰 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘶𝘴𝘦 𝘪𝘯 𝘢𝘤𝘤𝘰𝘳𝘥𝘢𝘯𝘤𝘦 𝘸𝘪𝘵𝘩 𝘢𝘱𝘱𝘭𝘪𝘤𝘢𝘣𝘭𝘦 𝘳𝘦𝘨𝘶𝘭𝘢𝘵𝘪𝘰𝘯𝘴 𝘪𝘯 𝘵𝘩𝘦 𝘜𝘯𝘪𝘵𝘦𝘥 𝘚𝘵𝘢𝘵𝘦𝘴 𝘢𝘯𝘥 𝘌𝘶𝘳𝘰𝘱𝘦.

31/07/2026

𝗡𝗲𝘄 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵: 𝗺𝗶𝗴𝗿𝗮𝗶𝗻𝗲 𝗺𝗮𝘆 𝗻𝗼𝘁 𝗳𝗶𝘁 𝗶𝗻𝘁𝗼 𝘁𝘄𝗼 𝗯𝗼𝘅𝗲𝘀 𝗮𝗳𝘁𝗲𝗿 𝗮𝗹𝗹

For decades, migraine has been split into two categories: episodic (fewer than 15 headache days a month) and chronic (15 or more). The distinction shapes how migraine is diagnosed, studied, and often treated.

A new meta-analysis puts that boundary to the test. Researchers analyzed data from 36,407 adults across 14 countries, including 10,226 people who met criteria for migraine. They looked at how headache characteristics, quality of life, and lost workdays changed as attack frequency increased, from less than one day a month up to daily.

What they found: no clear line at 15 days.
No sudden jump in symptoms or impact. Instead, burden increased gradually and continuously across the entire frequency range, regardless of whether someone had 5, 12, or 25 migraine days a month.

The researchers suggest migraine may be better understood as a single condition that varies in severity, rather than two categorically different diseases.

Two frequency markers still stand out as clinically useful: at 3 or fewer migraine days a month, preventive treatment is rarely needed; at 10 or more, the risk of medication overuse becomes a relevant concern. These findings are now informing the development of the next international headache classification, ICHD-4.

It's a reminder that disease burden doesn't stop at a frequency label. It's part of why we at Salvia BioElectronics look at migraine more broadly than the chronic/episodic line, including people whose migraine remains disabling despite multiple treatments, regardless of which side of that line they fall on.

📖 Husøy, A.K., Steiner, T.J. Is migraine a spectrum disorder? J Headache Pain 27, 163 (2026).

𝘔𝘺𝘚𝘢𝘭𝘷𝘪𝘢 𝘛𝘩𝘦𝘳𝘢𝘱𝘺 𝘪𝘴 𝘢𝘯 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘥𝘦𝘷𝘪𝘤𝘦, 𝘭𝘪𝘮𝘪𝘵𝘦𝘥 𝘵𝘰 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘶𝘴𝘦 𝘪𝘯 𝘢𝘤𝘤𝘰𝘳𝘥𝘢𝘯𝘤𝘦 𝘸𝘪𝘵𝘩 𝘢𝘱𝘱𝘭𝘪𝘤𝘢𝘣𝘭𝘦 𝘳𝘦𝘨𝘶𝘭𝘢𝘵𝘪𝘰𝘯𝘴 𝘪𝘯 𝘵𝘩𝘦 𝘜𝘯𝘪𝘵𝘦𝘥 𝘚𝘵𝘢𝘵𝘦𝘴 𝘢𝘯𝘥 𝘌𝘶𝘳𝘰𝘱𝘦.

25/07/2026

Sometimes a photo says more than words. Neurologists, headache specialists, pain physicians, and neurosurgeons, together with study coordinators and Salvia clinical team members from both Europe and the US, all came together in Chicago for our first official Investigator Meeting of RECLAIM-II, our soon to start US pivotal study.

Thank you for being part of this pioneering clinical research.

𝘔𝘺𝘚𝘢𝘭𝘷𝘪𝘢 𝘛𝘩𝘦𝘳𝘢𝘱𝘺 𝘪𝘴 𝘢𝘯 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘥𝘦𝘷𝘪𝘤𝘦, 𝘭𝘪𝘮𝘪𝘵𝘦𝘥 𝘵𝘰 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘶𝘴𝘦 𝘪𝘯 𝘢𝘤𝘤𝘰𝘳𝘥𝘢𝘯𝘤𝘦 𝘸𝘪𝘵𝘩 𝘢𝘱𝘱𝘭𝘪𝘤𝘢𝘣𝘭𝘦 𝘳𝘦𝘨𝘶𝘭𝘢𝘵𝘪𝘰𝘯𝘴 𝘪𝘯 𝘵𝘩𝘦 𝘜𝘯𝘪𝘵𝘦𝘥 𝘚𝘵𝘢𝘵𝘦𝘴 𝘢𝘯𝘥 𝘌𝘶𝘳𝘰𝘱𝘦.

09/07/2026

"The majority of people living with migraine are underdiagnosed, undertreated, and underserved." — Neurologist Amaal Starling, MD

Not everyone with migraine gets the same care. Where you live, the color of your skin, and even your gender can shape how quickly you're diagnosed and how well you're treated.

In a recent interview with the Migraine Science Collaborative, neurologist Dr. Amaal Starling of Mayo Clinic, Scottsdale, talked about the disparities she's worked to address throughout her career. Early on, she was struck by how often headache patients were met with dismissiveness before a clinician even saw them. Her response was to take on as many of those patients as she could.

She points to several gaps: women, two to three times more likely to live with migraine, are often told to just manage their stress. The American Indian and Alaska Native population has the highest prevalence of headache disorders, by her estimate nearly double the general population. Black and Hispanic communities remain undertreated even with equal access to care, according to a Harris Poll survey. And U.S. headache specialists cluster on the coasts, far from the middle of the country, which carries a high burden of migraine disease.

For Dr. Starling, closing these gaps starts with recognizing they're structural, and that real change happens through policy.

She also prescribes advocacy directly to her patients, as part of the treatment plan itself. Sharing your story, she says, connects people to a community that's both inclusive and diverse, and data from other chronic conditions like cardiovascular disease and diabetes suggests it carries real therapeutic value.

Read more in the article: https://migrainecollaborative.org/when-advocacy-is-part-of-the-treatment-plan-a-conversation-with-amaal-starling

Photo: Headache on the Hill, Alliance for Headache Disorders Advocacy, American Headache Society